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minimum data sets. ConClusions: The Saudi National e-health Strategy will 
leverage the ICD-10 implementation.
PHP3
Is Fda’s BreaktHrougH tHeraPy desIgnatIon a game-CHangIng trend 
For PatIents and Payers?
Aggarwal S., Topaloglu H.
Novel Health Strategies, Bethesda, MD, USA
objeCtives: In 2012 United States Food and Drug Administration (FDA) created 
a new expedited pathway of ‘Breakthrough Therapy Designation’ (BTD) to enable 
early approval of therapies, which have shown substantial activity in early trials. 
The objective of this study was to understand the impact on BTD on patients and 
payers. Methods: The data for number of granted BTDs was obtained from FDA.
gov. The data for publically disclosed BTDs was obtained from sponsor’s press 
releases. For all products the information for their mechanism of action, type of 
molecule, trial design, clinical efficacy and safety, and pricing and time to approval 
(for approved products) were obtained from peer-reviewed publications, confer-
ence abstracts, FDA and sponsor websites. Results: Since the establishment of the 
BTD pathway, 37 products have been granted breakthrough therapy designations 
(2012-2013), of which, 28 have been publically disclosed by the manufacturers and 
3 have been approved by the FDA. In terms of indications, 12 (43%) are for cancer, 
5 (18%) are for genetic diseases and 4 (14%) are for Hepatitis C Genotype 1. The 
three approved drugs with BTD are Gazyva, Imbruvica and Sovaldi. The median 
time to approval for these three drug was ~5 years, significantly shorter than the 
2012 median time to approval for priority review applications (6 years). However, 
the price premium was 30-50% compared to other drugs in the same category. Two 
of the drugs with BTD did not meet primary endpoint in their pivotal trial. While 
the BTD pathway promises to reduce development time, the high price is a major 
concern for payers and patients. ConClusions: BTD is a promising pathway to 
shorten development time and provides early access, however, high price could 
pose challenges for payers and patients.
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4 your kIds Care: reduCIng non-emergent HosPItalIzatIon In a 
medICaId PedIatrIC PoPulatIon tHrougH Hands-on traInIng and 
Parent/CaregIver eduCatIon
Grant M., Honeywell A., Dinsmore S., Keleti D., Michael K.E., Tan-Torres S., Higgins Y.L.
AmeriHealth Caritas Family of Companies, Philadelphia, PA, USA
objeCtives: As a Medicaid managed care organization (MCO), Keystone First 
experiences a high volume of pediatric members receiving care for common 
childhood illnesses at hospital emergency departments (EDs). The 4 Your Kids 
Care program educates parents/caregivers about what to do when their chil-
dren get sick, encourages members to engage their primary care physicians, 
and refers families to appropriate plan resources (e.g., 24/7 Nurse Hotline and 
Care Management). Methods: A 2.5-hour program educates parents/caregivers 
about treating common pediatric illnesses at home. The study group (SG) con-
sisted of participating parents/caregivers of 585 pediatric members (≤ 5 years old) 
in Philadelphia and Delaware counties (Pennsylvania) with at least one prior-
year non-emergent ED claim. The matched control group (CG) consisted of 1,189 
pediatric members with nonparticipating parents/caregivers in the pre-period 
and 1,153 in the post-period. The baseline period (January 1, 2010–December 31, 
2010) where non-urgent ED claims were collected was followed by the class period 
(January 1, 2011–September 30, 2011) and one-year follow-up period (October 1, 
2011–December 31, 2012). Participants completed a knowledge assessment both 
before commencement and after completion of the class. Results: While the 
average number of ED visits for non-urgent conditions decreased significantly dur-
ing the 12-month period in SG (p< 0.0001) and CG (p= 0.0097), the mean reduction 
for SG was more than three-fold greater than CG (-46.3% vs. -14.6%, respectively). 
Amounts paid for ED claims for non-urgent visits during the 12-month period for 
SG decreased by over twice the amount of CG (-37.8% vs. -17.4%). Questionnaire 
respondents displayed significant improvements in all six questions regarding 
knowledge assessment (p< 0.01). Participant evaluations of the program were 
overwhelmingly favorable. ConClusions: 4 Your Kids Care provided effective 
parent/caregiver education, improved health literacy, and significantly reduced 
non-emergent pediatric member ED utilization and costs.
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role oF PatIent InPut In tHe CedaC drug reImBursement deCIsIon 
makIng ProCess
Dionne P.A., Weicker S., Remple V, Tran T.
Pfizer Canada, Kirkland, QC, Canada
bACkgRound: Since 2010, the Canadian Agency for Drugs and Technologies 
in Health (CADTH), via the Common Drug Review (CDR), have allowed patient 
groups to submit issues and outcomes important to them to inform Canadian 
Expert Drug Advisory Committee (CEDAC) recommendations on drug reimburse-
ment. objeCtives: The objectives were to determine if the inclusion of patient 
input into the CDR process resulted in any change in the CEDAC positive fund-
ing recommendation (PFR) rate and to assess potential factors associated with 
a PFR. Methods: CEDAC recommendations (May 2004 to December 2013) were 
obtained from the CADTH website. “Efficacy” was defined as occurring when an 
outcome(s) identified as important to patients achieved statistically significant 
improvement versus placebo or similar/improved results versus active comparators. 
Trends in PFR were characterized using descriptive statistics and factors associated 
with a PFR were assessed using logistic regressions Results: The PFR rate for the 
153 recommendations published prior to the patient input process was 54% which 
was similar to the PFR rate (56%) for the 89 recommendations published after the 
process was established. A PFR rate of 58% was observed in the 65 submissions that 
included patient input and 50% in the 24 submissions without. Submissions that 
showed efficacy in outcomes important to patients had a similar PFR rate (60%) than 
if outcome scores for the levels are significantly different; (iii) Ascertain whether 
levels distinguish people of varying clinical profile (injury level and complete-
ness). Methods: A three-phase analytic approach involving quantitative and 
qualitative methodology was deployed: (a) SCI-FI items were ordered along a 
continuum of difficulty using IRT, and empirical item maps were generated from 
calibration study data (N= 855); (b) Delphi approach was employed with expert 
panel (n= 6) reviewing item maps and arriving at consensus for cut-off scores for 
level development; and (c) Developed levels were described and refined for mean-
ingful outcome interpretation. One-way ANOVAs were performed (levels as factor, 
SCI-FI CAT scores as dependent variable). Chi square analyses were performed to 
compare actual to expected number of persons at each level for the varied clini-
cal profiles, paraplegia-complete, paraplegia-incomplete, tetraplegia-complete 
and tetraplegia-incomplete. Results: Five levels representing varying range of 
functional outcomes were identified for all the SCI-FI domains except one hav-
ing four levels. ANOVA (pair-wise comparisons) results revealed significant score 
differences across levels. Chi-square tests were significant in the hypothesized 
direction. ConClusions: Developed levels define patient functional outcomes 
that provide meaningful interpretation of CAT scores for use in research and 
patient monitoring.
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eFFeCt oF Involvement on InFormatIon ProCessIng From over-tHe-
Counter drug FaCts Panel
Bhansali A.H., Sansgiry S.S.
University of Houston, Houston, TX, USA
objeCtives: The study objective was to assess the effect of involvement on infor-
mation processing from over-the-counter (OTC) Drug Facts panel. Methods: In 
this experimental, cross-sectional study the effect of extrinsic involvement when 
processing two experimental labels was evaluated. Labels designed based on con-
cepts of chunking, congruency and information placement were compared to the 
current OTC label. Extrinsic involvement was measured using a previously vali-
dated and reliable scale along with information processing variables measured 
using the OTC-label evaluation process model. The participants were tested for 
label comprehension, ease of use, attitude towards the label, product evaluation 
and purchase intention. Data was coded and analyzed using SAS® 9.3 at an apri-
ori significance level of 0.05. MANCOVA, ANCOVA, Dunnett’s post-hoc analyses 
were done to test the study objective. Results: Of the 249 survey participants 
(81.4% response rate) majority were females (55.4%) with a mean age of 36.8 (± 
9.6) years. Most of them had a college level education (54.2%) and worked in the 
health care field (61.4%). In general, extrinsic involvement scores were high (3.81 ± 
1.03). MANCOVA indicated a statistically significant effect of involvement between 
the label types (p< 0.0001). ANCOVA and Dunnett’s post hoc revealed that the level 
of involvement for attitude towards the label was significantly higher for Label 
A with warnings placed after the chunk (Uses, Directions, Other Information) as 
compared to Label B with warnings placed before the chunk and Label C, the current 
OTC label (p< 0.0001). ConClusions: Consumer involvement plays a significant 
role in information processing. Consumer attitude towards the label information 
is affected by their level of involvement. When the consumer is more involved he 
is more likely to understand the given information and have a favorable attitude 
towards the product.
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ICd-10 ImPlementatIon In saudI araBIa: CHallenges and 
oPPortunItIes! e-HealtH Is transFormIng medICal reCords to HealtH 
InFormatIon management!
Albishi H.A.
Ministry of Health, RIYADH, Saudi Arabia
objeCtives: ICD-10 is mandated by the World Health Organization (WHO). It 
codes diseases, signs and symptoms, abnormal findings, complaints, social cir-
cumstances, and external causes of injury or diseases. ICD-10 coding is used for 
measuring the quality, safety and efficacy of care, tracking public health concerns, 
epidemiological studies, and, improving clinical, financial, and administrative per-
formance. Accurate and precise coding utilizing standardized methodologies on 
a national scale is both challenging and meticulous process. This paper aims to 
highlight the implementation challenges of ICD-10 coding in Saudi Arabia from 
the year (2007) to the year (2014). The main challenges and opportunities observed 
during the implenetaion process will be presented. Methods: The methodology 
of the implementation process of ICD-10 started in 2007, the first step started with 
signing an agreement between the Saudi Arabia and Australia to obtain a license 
agreement, the second step was creating a committee to oversee the implementa-
tion, and the third step was preparing an implementation guide with the following 
objectives, to increase the level of awareness to understand the ICD-10 impact, 
and enable hospitals and software vendors to adopt to the new system. Results: 
ICD-10 implantation faced some challenges, some were coders-related and some 
were organization-related. Among the most important coders challenges were the 
lack of ICD-10 training resources, poor English literacy, and significant shortage of 
coders (7%) and medical records staff (45%). The absence of a clear professional 
career path for Hospital Information Management (HIM) Specialists and Clinical 
Coders has played an important role in limiting the coding process in Saudi Arabia. 
Organization challenges included lack of ICD-10 awareness, poor technical infra-
structure, lack of interoperability with legacy and dated Hospital Information 
Systems, and the lack of a Discharge Abstract Data (DAD) System with defined 
